Sagimet Biosciences closes USD 115 million underwritten Series A common stock, pre-funded warrant offering

Bitget2026/10/01 20:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sagimet Biosciences closed an underwritten offering of 8,750,010 shares of Series A common stock priced at USD 10.00.
Investors also bought pre-funded warrants to purchase 2,750,010 Series A common shares at USD 9.9999 each.
Pre-funded warrants carry a USD 0.0001 exercise price, exercisable immediately.
Gross proceeds totaled about USD 115 million before underwriting discounts, commissions, and offering expenses.
Net proceeds earmarked for Phase 3 denifanstat acne trial, pre-launch work, TVB-3567 through Phase 2 topline, other R&D, general purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011631PRIMZONEFULLFEED9838257) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sagimet Biosciences closes USD 115 million underwritten Series A common stock, pre-funded warrant offering

You may also like

Crypto prices